Nephros Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference

RIVER EDGE, NJ / ACCESSWIRE / August 29, 2016 / Nephros, Inc. (OTCQB: NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis (“HD”) machine for the treatment of patients with end stage renal disease (“ESRD”), today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.

Daron Evans, President and CEO of Nephros, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Event: 18th Annual Rodman & Renshaw Global Investment Conference

Date: September 13, 2016

Time: 4:15 (Eastern Time)

Location: The Louis Room; Lotte New York Palace Hotel in New York City

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its ultrafilters are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. In the hospital setting, Nephros ultrafilters are used as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients. Nephros ultrafilters are also available for a number of industrial, food service, commercial and military applications.

For more information about Nephros, please visit the company’s website at www.nephros.com.

Contact:

Investor:
PCG Advisory Group
Kirin M. Smith, Chief Operating Officer
Direct: 646-863-6519
www.pcgadvisory.com

SOURCE: Nephros, Inc.

ReleaseID: 444331